Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sunitinib + FOLFIRI is an investigational combination therapy used in clinical trials for the treatment of metastatic colorectal cancer (mCRC). Sunitinib is a small molecule multi-targeted tyrosine kinase inhibitor that blocks several receptors involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, FLT3, RET, and CSF1R. By inhibiting these kinases, sunitinib disrupts tumor blood supply and cell signaling pathways essential for cancer growth. FOLFIRI is a standard chemotherapy regimen composed of three drugs: folinic acid (leucovorin), which enhances the efficacy of fluorouracil; fluorouracil (5-FU), an antimetabolite that inhibits DNA synthesis; and irinotecan, a topoisomerase I inhibitor that prevents DNA replication. The combination aims to leverage both targeted antiangiogenic effects from sunitinib with cytotoxic effects from chemotherapy to improve outcomes in mCRC patients[1][2][3][4].
- Other names
- sunitinib malate + FOLFIRIsunitinib + folinic acid, fluorouracil, and irinotecan
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sunitinib + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + FOLFIRI.